Search Results - "COBLEIGH, Melody A"

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane by BURSTEIN, Harold J, ELIAS, Anthony D, BAUM, Charles M, MILLER, Kathy D, RUGO, Hope S, COBLEIGH, Melody A, WOLFF, Antonio C, EISENBERG, Peter D, LEHMAN, Mary, ADAMS, Bonne J, BELLO, Carlo L, DEPRIMO, Samuel E

“…Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor…”
Get full text

Other Options in the Treatment of Advanced Breast Cancer by Cobleigh, Melody A

“…Many cytotoxic therapies are available for patients with metastatic breast cancer, but response rates are low and acquired or de novo resistance is virtually…”
Get full text

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer by MILLER, Kathy D, CHAP, Linnea I, LANGMUIR, Virginia, RUGO, Hope S, HOLMES, Frankie A, COBLEIGH, Melody A, MARCOM, P. Kelly, FEHRENBACHER, Louis, DICKLER, Maura, OVERMOYER, Beth A, REIMANN, James D, SING, Amy P

“…This randomized phase III trial compared the efficacy and safety of capecitabine with or without bevacizumab, a monoclonal antibody to vascular endothelial…”
Get full text

Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells by DiScala, Molly, Najor, Matthew S, Yung, Timothy, Morgan, Deri, Abukhdeir, Abde M, Cobleigh, Melody A

“…Approximately 20% of breast cancers are HER2-positive. Trastuzumab has improved patient outcomes significantly for these cancers. However, acquired resistance…”
Get full text

Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination by Chowdhary, Mudit, MD, Sen, Neilayan, MD, Chowdhary, Akansha, MD, Usha, Lydia, MD, Cobleigh, Melody A., MD, Wang, Dian, MD, PhD, Patel, Kirtesh R., MD, Barry, Parul N., MD, Rao, Ruta D., MD

“…AbstractPurposePalbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests…”
Get full text

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer by VOGEL, Charles L, COBLEIGH, Melody A, SHAK, Steven, STEWART, Stanford J, PRESS, Michael, TRIPATHY, Debu, GUTHEIL, John C, HARRIS, Lyndsay N, FEHRENBACHER, Louis, SLAMON, Dennis J, MURPHY, Maureen, NOVOTNY, William F, BURCHMORE, Michael

“…To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. One hundred fourteen…”
Get full text

Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin by Turturro, Sanja B., Najor, Matthew S., Ruby, Carl E., Cobleigh, Melody A., Abukhdeir, Abde M.

“…A review of the literature finds that women diagnosed with breast cancer, who were on an aspirin regimen, experienced a decreased risk of distant metastases…”
Get full text

Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer by JUBB, Adrian M, MILLER, Kathy D, CHEN, Daniel S, KOEPPEN, Hartmut, RUGO, Hope S, HARRIS, Adrian L, DAFENG CHEN, REIMANN, James D, COBLEIGH, Melody A, SCHMIDT, Maike, LANGMUIR, Virginia K, HILLAN, Kenneth J

“…The addition of bevacizumab to cytotoxic chemotherapy has demonstrated a progression-free survival (PFS) benefit in the first-line and second-line treatment of…”
Get full text

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43 by Siziopikou, Kalliopi P., Anderson, Stewart J., Cobleigh, Melody A., Julian, Thomas B., Arthur, Douglas W., Zheng, Ping, Mamounas, Eleftherios P., Pajon, Eduardo R., Behrens, Robert J., Eakle, Janice F., Leasure, Nick C., Atkins, James N., Polikoff, Jonathan A., Seay, Thomas E., McCaskill-Stevens, Worta J., Rabinovitch, Rachel, Costantino, Joseph P., Wolmark, Norman

“…NSABP B-43 is the first prospective, randomized phase III multi-institution clinical trial targeting high-risk, HER2-positive DCIS. It compares whole breast…”
Get full text

Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment by O'Connell, Brenda C, Hubbard, Charley, Zizlsperger, Nora, Fitzgerald, Donna, Kutok, Jeffrey L, Varner, Judith, Ilaria, Robert, Cobleigh, Melody A, Juric, Dejan, Tkaczuk, Kate H R, Elias, Anthony, Lee, Arielle, Dakhil, Shaker, Hamilton, Erika, Soliman, Hatem, Peluso, Stephane

“…BackgroundTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor prognosis particularly in the metastatic setting…”
Get full text

Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes by COBLEIGH, Melody A, TABESH, Bita, BITTERMAN, Pincas, BAKER, Joffre, CRONIN, Maureen, LIU, Mei-Lan, BORCHIK, Russell, MOSQUERA, Juan-Miguel, WALKER, Michael G, SHAK, Steven

“…Purpose: This study, along with two others, was done to develop the 21-gene Recurrence Score assay (Oncotype DX) that was validated in a subsequent independent…”
Get full text

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002 by WINER, Eric P, HUDIS, Clifford, BRAUN, Susan, COBLEIGH, Melody A, LANGER, Amy S, PEROTTI, Judy, POWLES, Trevor J, WHELAN, Timothy J, BROWMAN, George P, BURSTEIN, Harold J, CHLEBOWSKI, Rowan T, INGLE, James N, EDGE, Stephen B, MAMOUNAS, Eleftherios P, GRALOW, Julie, GOLDSTEIN, Lori J, PRITCHARD, Kathleen I

“…To conduct an evidence-based technology assessment to determine whether the routine use of anastrozole or any of the aromatase inhibitors in the adjuvant…”
Get full text

Reply to M. R. Van Bockstal et al by Cobleigh, Melody A, Anderson, Stewart J

Get full text

Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers by Cobleigh, Melody A., Layng, Kayla Viets, Mauer, Elizabeth, Mahon, Brett, Hockenberry, Adam J., Abukhdeir, Abde M.

“…Purpose The PIK3R1 gene encodes the regulatory subunit—p85a—of the PI3K signaling complex. Prior studies have found that pathogenic somatic alterations in…”
Get full text

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2 -Overexpressing Metastatic Breast Cancer by Vogel, Charles L, Cobleigh, Melody A, Tripathy, Debu, Gutheil, John C, Harris, Lyndsay N, Fehrenbacher, Louis, Slamon, Dennis J, Murphy, Maureen, Novotny, William F, Burchmore, Michael, Shak, Steven, Stewart, Stanford J, Press, Michael

“…To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with -overexpressing metastatic breast cancer. One hundred fourteen women…”
Get full text

A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer by MILLER, Kathy D, SAPHNER, Thomas J, WATERHOUSE, David M, CHEN, T.-T, RUSH-TAYLOR, Anita, SPARANO, Joseph A, WOLFF, Antonio C, COBLEIGH, Melody A, GALBRAITH, Susan, SLEDGE, George W

“…Purpose: This pilot trial was performed to evaluate the safety, pharmacokinetics and feasibility of incorporating BMS-275291, a matrix metalloproteinase…”
Get full text

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease by Cobleigh, Melody A, Vogel, Charles L, Tripathy, Debu, Robert, Nicholas J, Scholl, Susy, Fehrenbacher, Louis, Wolter, Janet M, Paton, Virginia, Shak, Steven, Lieberman, Gracie, Slamon, Dennis J

“…Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety…”
Get full text

Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway by Turturro, Sanja B., Najor, Matthew S., Yung, Timothy, Portt, Liam, Malarkey, Christopher S., Abukhdeir, Abde M., Cobleigh, Melody A.

“…Purpose The PI3K pathway, which includes the PI3K catalytic subunits p110α (PIK3CA) and the PI3K regulatory subunit p85α (PIK3R1), is the most frequently…”
Get full text

Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial by Cobleigh, Melody A, Anderson, Stewart J, Siziopikou, Kalliopi P, Arthur, Douglas W, Rabinovitch, Rachel, Julian, Thomas B, Parda, David S, Seaward, Samantha A, Carter, Dennis L, Lyons, Janice A, Dillmon, Melissa S, Magrinat, Gustav C, Kavadi, Vivek S, Zibelli, Allison M, Tiriveedhi, Lavanya, Hill, Matthew L, Melnik, Marianne K, Beriwal, Sushil, Mamounas, Eleftherios P, Wolmark, Norman

“…Preclinical studies report that trastuzumab (T) can boost radiotherapy (RT) effectiveness. The primary aim of the B-43 trial was to assess the efficacy of RT…”
Get full text

First-line Herceptin monotherapy in metastatic breast cancer by Vogel, C L, Cobleigh, M A, Tripathy, D, Gutheil, J C, Harris, L N, Fehrenbacher, L, Slamon, D J, Murphy, M, Novotny, W F, Burchmore, M, Shak, S, Stewart, S J

“…The pivotal phase II and III Herceptin trials proved the efficacy and safety of second- or third-line single-agent Herceptin and first-line Herceptin in…”
Get more information